Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713087 | 0.95 | SMN1; SMN2 (0.48) | UTS2RCNR1SMN1; SMN2STSTP53 | |
| SCHEMBL12713105 | 0.94 | SMN1; SMN2 (0.49) | UTS2RCNR1SMN1; SMN2TP53LMNA | |
| SCHEMBL12713082 | 0.89 | ALDH1A1 (0.47) | SMN1; SMN2TP53LMNAMEN1KMT2A | |
| SCHEMBL12713042 | 0.86 | CYP1A2 (0.49) | CYP1A2CYP2D6CYP2C19SMN1; SMN2TP53 | |
| SCHEMBL12713162 | 0.83 | CNR1 (0.44) | UTS2RCNR1SMN1; SMN2STSTP53 | |
| SCHEMBL12713094 | 0.83 | SCN9A (0.47) | TP53POLBLMNAHPGD | |
| SCHEMBL12713241 | 0.83 | CHRNB2 (0.45) | UTS2RCNR1SMN1; SMN2STSTP53 | |
| SCHEMBL12713160 | 0.83 | ADAM17 (0.44) | CNR1SMN1; SMN2STSTP53POLB | |
| SCHEMBL12713141 | 0.82 | SMN1; SMN2 (0.47) | UTS2RCNR1SMN1; SMN2STSTP53 | |
| SCHEMBL12713099 | 0.82 | MEN1 (0.52) | CNR1SMN1; SMN2STSTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| WO-2009015867-A1 | SUBSTITUTED ARYL OR HETEROARYLPIPERDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| EP-2020405-A1 | Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007115798-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | UTS2R 1096/4885CYP1A2 2577/4885CYP2D6 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.